Method for preparing asenapine

A novel synthesis method for asenapine using intramolecular nucleophilic substitution and diazotization deamination under mild conditions addresses the challenges of existing methods, achieving high yield and purity suitable for industrial production.

JP7584496B2Active Publication Date: 2024-11-15CHOCHIAN OUSUN PHARM CO LTD
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2022508803
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2019-08-13
Filing Date
2020-08-11
Publication Date
2024-11-15
Estimated Expiration
2040-08-11

AI Technical Summary

Technical Problem

Current synthesis methods for asenapine face challenges such as complicated operations, environmental pollution, use of flammable and explosive reagents, and long synthetic routes, making them unsuitable for industrial production.

Method used

A new method involving intramolecular nucleophilic substitution, catalytic hydrogenation, diazotization deamination, and recrystallization to produce asenapine, using mild conditions and safer reagents, resulting in a high-yield, pure crystalline form suitable for industrial production.

Benefits of technology

The method simplifies operations, reduces environmental impact, and lowers production costs, providing a high-purity crystalline form of asenapine suitable for large-scale industrial use.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007584496000037
    Figure 0007584496000037
  • Figure 0007584496000038
    Figure 0007584496000038
  • Figure 0007584496000039
    Figure 0007584496000039
Patent Text Reader

Abstract

The present invention relates to methods for preparing asenapine. Specifically, the present invention relates to methods for preparing pharmaceutically acceptable asenapine free base and crystalline forms thereof, as well as methods for preparing intermediate compounds used in the methods.
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to the field of organic compound synthesis. In particular, the present invention relates to a method for preparing the antipsychotic drug asenapine, i.e. the compound trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]-oxepino[4,5-c]pyrrole and its novel crystalline form. [Background technology]

[0002] Asenapine refers to the compound trans-5-chloro-2-methyl-2,3,3a,12b-tetrahydro-1H-dibenzo[2,3:6,7]-oxepino[4,5-c]pyrrole. Its maleate salt can be used for the acute treatment of schizophrenia, mania or mixed bipolar disorder type I in adults. The mechanism of action of asenapine may be related to the antagonism of dopamine D2 and serotonin 2A. It is suitable for use in the treatment of mania or mixed episodes of schizophrenia and bipolar disorder type I, and has good antipsychotic effects. Antipsychotics are currently the fifth largest therapeutic category after cholesterol-lowering agents, with a market size of US$16.2 billion in the global market. In China, the antipsychotic market has maintained an average annual growth rate of more than 40%, and the market share of antischizophrenic drugs is about 30%, which is growing at an average annual growth rate of 9.8%. Therefore, it is necessary to research and develop a new method for preparing asenapine that is suitable for industrial production.

[0003] Up to now, many publications and patents have reported the synthesis of asenapine.First, US4145434 and publications (Vader, J.; Kaspersen, F.; Sperling, E.; Schlachter, I.; Terpstra, A.; Hilberink, P.; Wagenaars, GJ Labelled Compd. Radiopharm. 1994, 34, 845-869) respectively report a method for preparing asenapine.The synthetic route is as follows:

[0004] [ka]

[0005] The main problem with this synthetic route is that the obtained asenapine is a mixture of cis and trans isomers, the separation operation of the isomers is very complicated, and the yield is low, therefore, this method is difficult to use in industrial production.

[0006] A 2008 paper (Org. Process Res. Dev., 2008, 12 (2), 196-201) reported an improvement to the above synthesis method. The method is as follows:

[0007] [ka]

[0008] The feature of this method is that the lactam ring is hydrolyzed and opened using a strong base, isomerization reaction occurs simultaneously, then ring closure to obtain the desired translactam intermediate, and finally reduction to asenapine by lithium aluminum hydride. This improvement solves the problems in product separation and purification, and improves the overall yield. However, this synthetic route is long, and the starting material 2-(5-chloro-2-phenoxy)phenylacetic acid must be synthesized by the following method. In addition, the above method involves multiple reactions using environmentally harmful and dangerous reagents, such as lithium aluminum hydride, and therefore is not conducive to industrial production.

[0009] [ka]

[0010] Later, in 2008, US2008009619 reported using o-bromobenzyl bromide as the raw material to react with triethyl phosphite to obtain benzyl phosphonate, which was then reacted with salicylaldehyde via Horner-Wadsworth-Emmons reaction to obtain trans-tetrahydropyrrole intermediate, and finally the desired compound was obtained by intramolecular Ullmann reaction.

[0011] [ka]

[0012] Although this method has a short synthetic route and can obtain a single isomer, it requires the use of o-bromobenzyl bromide to prepare benzyl phosphonate, which is a highly irritating raw material and requires a long and high-temperature reaction. Moreover, the Ullmann reaction in the final step has a low yield and requires a long and high-temperature reaction in the presence of cesium carbonate, cuprous halide and N,N-dimethylglycine, therefore, it brings about high production costs as well as environmental pollution problems.

[0013] Similar to the above synthetic method, a novel synthetic route for asenapine was reported in 2011 in CN102229613.

[0014] [ka]

[0015] In this method, 2-bromo-β-nitro-styrene and 2-methoxy-5-chlorophenylacetic acid methyl ester are used as starting materials, and a mixture of cis and trans isomers is obtained by condensation, reduction, cyclization and methylation, and then subjected to de-etherification, intramolecular Ullmann cyclization and reduction to obtain the desired product asenapine. This synthesis method can obtain a single trans compound by isomerization of the mixture of cis and trans isomers, simplifying the operation and improving the yield. However, this method uses n-butyllithium, which needs to be controlled at a temperature below -60°C, and flammable and explosive LiAlH is used for lactam reduction. 4 is required, which limits the reaction in industrial production.

[0016] Recently, CN104974168 reported a method for preparing asenapine and an intermediate for preparing asenapine in 2015. This method uses 2-chloro-5-nitrobenzaldehyde and o-methoxyphenylacetonitrile as starting materials, which undergo condensation, addition and cyclization reactions to obtain a single trans isomer, and then the desired product asenapine is obtained by substitution, reduction, de-etherification, cyclization and diazotization. However, this synthesis method requires the use of highly toxic cyanide and flammable and explosive reagent LiAlH 4 It is necessary to use. There is a risk in industrial production.

[0017] [ka]

[0018] In summary, the currently reported synthetic methods of asenapine generally have the disadvantages of complicated operation, serious environmental pollution, flammable and explosive reagents used, and long synthetic route.Therefore, it is necessary to further research a simple and efficient synthetic method of asenapine suitable for industrialization. [Prior art documents] [Patent documents]

[0019] [Patent Document 1] US4145434 [Patent Document 2] US2008009619 [Patent Document 3] CN102229613 [Patent Document 4] CN104974168 [Non-patent literature]

[0020] [Non-Patent Document 1] J. Labeled Compd. Radiopharm. 1994, 34, 845-869 [Non-Patent Document 2] Org. Process Res. Dev., 2008, 12 (2), 196-201 Summary of the Invention

[0021] In order to overcome the shortcomings of the above routes, the present invention provides a novel synthesis method for asenapine, which has the advantages of simple operation, high product yield, good purity of intermediates and target products, and is easy for industrial production.

[0022] Throughout the specification, the following terms have the meanings indicated below.

[0023] "C 5-9 "Alkane" refers to a straight or branched alkane having 5 to 9 carbon atoms, such as pentane, n-pentane, hexane, n-hexane or n-heptane.

[0024] "C 1-6 Alkyl" and "C 1-4 "Alkyl" refers to straight-chain or branched alkyl having 1 to 6 or 1 to 4 carbon atoms, respectively, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, and tert-butyl.

[0025] "Halo" or "halogen" refers to fluoro, chloro, bromo or iodo.

[0026] The "Huisgen cycloaddition" is a cycloaddition reaction that occurs between a 1,3-dipole and an alkene, alkyne, or corresponding derivative, and the product is a five-membered heterocyclic compound. The alkene compound is called the dipolarophile in the reaction. The German chemist Rolf Huisgen was the first to use this type of reaction extensively to prepare five-membered heterocyclic compounds, hence it is also known as the Huisgen reaction.

[0027] "Diazotization deamination reaction" means that the diazotization of an amino group is used in combination with a reaction to replace the diazo group with a hydrogen atom as a method to remove the amino group, called diazotization deamination reaction, i.e., the amino group is subjected to diazotization to obtain a diazo compound, which is then reacted with a reducing agent to obtain a deaminated compound in which the diazo group is replaced with a hydrogen atom.

[0028] The object of the present invention is to provide a novel process for preparing asenapine, which results in a novel crystalline form of asenapine free base.

[0029] In a first aspect, the present invention provides a compound of formula I

[0030] [ka] A method for preparing asenapine of formula (I), comprising the steps of: (a-1) A step of subjecting intermediate II to an intramolecular nucleophilic substitution reaction under basic conditions to obtain a cyclic ether intermediate III

[0031] [ka] wherein X is F, Cl, Br or I, and the base is an alkali metal hydroxide, an alkali metal carbonate, an alkali metal bicarbonate, a metal hydride, an organometallic compound or a strong non-nucleophilic organic base; (a-2) reducing the nitro group of intermediate III to obtain intermediate IV;

[0032] [ka] (a-3) subjecting intermediate IV to a diazotization deamination reaction and then purifying it by recrystallization to obtain the pure product asenapine of formula I.

[0033] [ka] The present invention provides a method comprising:

[0034] In the above step (a-1), intermediate II is reacted with a phenolic hydroxyl group on another benzene ring in an aprotic solvent under basic and mild conditions to carry out an intramolecular nucleophilic substitution reaction to obtain a cyclic ether intermediate III.

[0035] The bases used in this process are alkali metal hydroxides LiOH, NaOH, KOH, RbOH, CsOH, FrOH, alkali metal carbonates Li 2 CO 3 , Na 2 CO 3 , K 2 CO 3 , Rb 2 CO 3 , Cs 2 CO 3 , alkali metal hydrogen carbonate NaHCO 3 , K.H.C.O. 3 , organometallic compounds butyllithium, methylmagnesium chloride, tert-butylmagnesium chloride, ethylmagnesium bromide, butylmagnesium bromide, metal hydrides NaH, KH, CaH 2 and the strong non-nucleophilic organic bases LDA, LiHMDS or NaHMDS.

[0036] The solvent in the reaction is an aprotic solvent, for example, selected from toluene, xylene, tetrahydrofuran, methyl tetrahydrofuran, diethyl ether, isopropyl ether, methyl tert-butyl ether, dioxane, acetonitrile, sulfolane, N-methylpyrrolidone, DMF, DMSO, glycol dimethyl ether, diethylene glycol dimethyl ether, or a mixture of two or more thereof.

[0037] The reaction temperature is 0 to 100°C, preferably 20 to 70°C.

[0038] After the reaction is complete, the mixture is cooled to room temperature, and drinking water is added thereto to precipitate the product, which is filtered and dried under vacuum to constant weight to obtain the cyclic ether intermediate III.

[0039] In the above step (a-2), the nitro group of the intermediate III is reduced by catalytic hydrogenation to obtain the intermediate IV.

[0040] The solvent used in this process is C 1-4 The solvent may be an alcohol, such as methanol, ethanol, propanol, isopropanol, butanol, isobutanol, tert-butanol, or water, or a mixture of two or more thereof.

[0041] The reaction temperature is 30 to 70°C.

[0042] The nitro group of intermediate III is reduced to amino by catalytic hydrogenation in the reaction, where the reducing agent used can be selected from Pd / C, Ni, iron, zinc or sodium sulfide.

[0043] In said step (a-3), intermediate IV is subjected to a diazotization deamination reaction and then purified by recrystallization to obtain the pure product asenapine of formula I.

[0044] Intermediate IV is dissolved in a reducing agent for diazotization deamination reaction, and diazotization reagent is added dropwise thereto in a one-pot reaction at -5 to 30°C. The pH value is adjusted to neutral with a base, and then a solid is precipitated, which is filtered to obtain the crude product, and then recrystallized to obtain asenapine in crystalline form.

[0045] The diazotizing reagent used in this reaction is a nitrite, such as sodium nitrite or potassium nitrite.

[0046] The reducing agent used in the diazotization deamination reaction in this reaction can be selected from methanol, ethanol, isopropanol, hypophosphorous acid, borohydride (including sodium borohydride, potassium borohydride) or nitrite.

[0047] The nitrite is selected from methyl nitrite, ethyl nitrite, tert-butyl nitrite, n-pentyl nitrite or isoamyl nitrite.

[0048] The base used in this step may be selected from sodium hydroxide, potassium hydroxide, sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, ammonia, aqueous methylamine or triethylamine.

[0049] The solvent used in the purification by recrystallization is C 5-9The solvent is selected from an alkane (e.g., n-pentane, hexane, n-hexane or n-heptane or a mixture of two or more thereof), an aromatic hydrocarbon solvent (e.g., benzene, toluene, xylene, chlorobenzene or a mixture of two or more thereof), an ester solvent (e.g., ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, tert-butyl acetate or a mixture of two or more thereof), a ketone solvent (e.g., acetone, butanone or a mixture thereof), an ether solvent (e.g., diethyl ether, isopropyl ether, methyl tert-butyl ether, tetrahydrofuran, methyl tetrahydrofuran or a mixture of two or more thereof), an alcohol solvent (e.g., methanol, ethanol, propanol, isopropanol or a mixture of two or more thereof), water, or a mixture of two or more of the above solvents, preferably n-heptane or a mixture thereof with other solvents.

[0050] In a second embodiment, a method for preparing asenapine of formula I is provided, comprising the steps of:

[0051] [ka] wherein intermediate IV is subjected to a diazotization deamination reaction and then purified by recrystallization to obtain the pure product asenapine of formula I.

[0052] Intermediate IV is dissolved in a reducing agent used in the diazotization deamination reaction, to which the diazotization reagent is added dropwise at −5 to 30° C. in a one-pot reaction. The pH value is adjusted to neutral with a base, and then a solid precipitates out, which is filtered to obtain the crude product, which is then recrystallized to obtain asenapine in crystalline form.

[0053] The diazotizing reagent used in this reaction is a nitrite, such as sodium nitrite or potassium nitrite.

[0054] The reducing agent used in the diazotization deamination reaction in this reaction can be selected from methanol, ethanol, isopropanol, hypophosphorous acid, borohydride (including sodium borohydride, potassium borohydride) or nitrite.

[0055] The nitrite is selected from methyl nitrite, ethyl nitrite, tert-butyl nitrite, n-pentyl nitrite or isoamyl nitrite.

[0056] In a third aspect, the present invention provides crystals of asenapine of formula I and methods for preparing the crystals.

[0057] The present invention provides a crystalline form of asenapine of formula I, characterized in that when powder X-ray diffraction analysis is performed under experimental conditions using CuKα radiation, the characteristic diffraction positions, expressed in 2θ angles, are 9.0±0.2°, 11.2±0.2°, 18.0±0.2°, 22.1±0.2°, 22.4±0.2° and 22.6±0.2°.

[0058] More specifically, in the PXRD pattern of crystalline asenapine of formula I, the characteristic diffraction positions, expressed in 2θ angles, are 9.0±0.2°, 10.9±0.2°, 11.2±0.2°, 18.0±0.2°, 19.4±0.2°, 19.7±0.2°, 21.5±0.2, 22.1±0.2°, 22.4±0.2°, 22.6±0.2° and 25.3±0.2°.

[0059] The PXRD pattern of the crystalline asenapine of formula I is shown in FIG. 1, its IR pattern is shown in FIG. 2, and its DSC pattern is shown in FIG.

[0060] Using the preparation and purification methods of the present invention, a crystalline form of asenapine of formula I is obtained, which is characterized in that when powder X-ray diffraction analysis is performed under experimental conditions with CuKα radiation, the diffraction positions 2θ angle (°) or d value (Å), and peak heights (height %) or peak area values ​​(area %) representing the relative intensities of the diffraction peaks are as follows:

[0061] [Table 1]

[0062] The process for preparing the crystalline form of asenapine having formula I comprises dissolving crude asenapine in a recrystallization solvent, crystallizing under stirring at room temperature, filtering, and drying under vacuum to obtain asenapine free base in the form of said crystalline form.

[0063] The solvent used in the purification by recrystallization is C 1-9 The solvent is selected from an alkane (e.g., n-pentane, hexane, n-hexane or n-heptane or a mixture of two or more thereof), an aromatic hydrocarbon solvent (e.g., benzene, toluene, xylene, chlorobenzene or a mixture of two or more thereof), an ester solvent (e.g., ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, tert-butyl acetate or a mixture of two or more thereof), a ketone solvent (e.g., acetone, butanone or a mixture thereof), an ether solvent (e.g., diethyl ether, isopropyl ether, methyl tert-butyl ether, tetrahydrofuran, methyltetrahydrofuran or a mixture of two or more thereof), an alcohol solvent (e.g., methanol, ethanol, propanol, isopropanol or a mixture of two or more thereof), water, or a mixture of two or more of the above solvents, preferably n-heptane or a mixture thereof with other solvents.

[0064] In one embodiment, a method for preparing a crystalline form of asenapine having formula I comprises adding a recrystallization solvent, such as hexane, n-hexane or n-heptane, or a mixture thereof with toluene, xylene, ethyl acetate, isopropyl acetate, isopropyl ether, tetrahydrofuran or methyltetrahydrofuran, to crude asenapine, dissolving it by heating and stirring, followed by cooling to precipitate a solid, which is collected by filtration and dried under vacuum to obtain the crystalline compound of formula I.

[0065] The temperature for dissolving is 30 to 70°C, preferably 35 to 50°C.

[0066] The temperature for precipitating the crystals is 15-25°C. After maintaining the temperature of 15-25°C for 1.0-1.5 hours to precipitate the crystals, the temperature is lowered to -20-0°C, preferably -20--10°C, at a rate of 5-10°C / hour. After maintaining the mixture at that temperature with stirring for 1.0-1.5 hours, the mixture is filtered and washed with an appropriate amount of hexane, n-hexane or n-heptane. The resulting product is filtered and vacuum dried at 30-60°C to obtain the crystalline compound of formula I.

[0067] In other embodiments, a method for preparing a crystalline form of asenapine having formula I includes adding a recrystallization solvent, such as acetone, methanol, ethanol, propanol, or isopropanol, to crude asenapine, dissolving it by heating and stirring, and then cooling to precipitate a solid, or adding a mixture of acetone, methanol, ethanol, propanol, or isopropanol and water to crude asenapine, dissolving it by heating and stirring, and then cooling to precipitate a solid, and collecting the resulting solid by filtration and drying under vacuum to obtain the crystalline compound of formula I.

[0068] The temperature for dissolving is 30 to 70°C, preferably 35 to 50°C.

[0069] The temperature for precipitating the crystals is 20-25°C. After maintaining the temperature of 20-25°C for 1.0-1.5 hours to precipitate the crystals, the temperature is lowered to -5-15°C, preferably -5-5°C, at a rate of 5-10°C / hour. After maintaining the mixture at that temperature with stirring for 1.0-1.5 hours, the mixture is filtered and washed with an appropriate amount of recrystallization solvent. The resulting product is filtered and vacuum dried at 30-60°C to obtain the crystalline compound of formula I.

[0070] The method for preparing the crystals of asenapine of formula I may further include dissolving the asenapine acid salt in water or an organic solvent and neutralizing it with a corresponding equivalent amount of base. The resulting solution is extracted with an aprotic solvent and concentrated to dryness, and then the crystals are prepared by the above-mentioned recrystallization method.

[0071] The organic solvent used for dissolving may be selected from methanol, ethanol, isopropanol, N-methylpyrrolidone, DMF, DMSO, acetonitrile, tetrahydrofuran or methyltetrahydrofuran.

[0072] Asenapine acid salts may be selected from the hydrochloride, hydrobromide, hydroiodide, maleate, fumarate or tartrate salts.

[0073] The base may be selected from sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate, cesium carbonate, lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium tert-butoxide or potassium tert-butoxide.

[0074] The aprotic organic solvent may be selected from hexane, n-hexane, n-heptane, toluene, xylene, isopropyl ether, methyl tert-butyl ether or a mixture of two or more thereof.

[0075] The resulting asenapine of formula I can also be salted with an acid to prepare pharma- ceutically acceptable salts, including reacting asenapine with hydrochloric acid to form a salt to prepare asenapine hydrochloride, or reacting asenapine with maleic acid to form a salt to prepare asenapine maleate.

[0076] In a fourth aspect, the present invention provides a compound of formula II having the structure:

[0077] [ka] wherein X is F, Cl, Br or I.

[0078] Specifically, compounds of formula II include the following four compounds:

[0079] [ka]

[0080] The present invention further provides a process for preparing a compound of formula II, comprising the steps of:

[0081] [ka]

[0082] In the above step (b-1), 2-halo-5-nitrobenzenemethanol (V) is reacted with sulfuric acid and hydrohalic acid to replace the hydroxyl group in the structure with a halogen atom, and then reacted with triethyl phosphite in an aprotic organic solvent under the catalytic action of a Lewis acid to obtain intermediate VI.

[0083] The hydrohalic acid used in this step includes hydrofluoric acid, hydrochloric acid, hydrobromic acid, or hydroiodic acid. The Lewis acid is FeCl 2 , FeCl 3 , FeBr 3 , ZnCl 2 , ZnBr 2 or InBr 2 It is.

[0084] The aprotic organic solvent may be selected from dichloromethane, chloroform, tetrahydrofuran, methyltetrahydrofuran, benzene, toluene, xylene, chlorobenzene, and the like, or a mixture of two or more thereof.

[0085] Specifically, compound V (2-halo-5-nitro-benzyl alcohol), hydrohalic acid and sulfuric acid are mixed in a weight ratio of 1.0:1.2-3.0:0.2-1.0 equivalents, and then heated to 20-55°C. The reaction mixture is maintained at that temperature with stirring for 5-14 hours, then extracted with an aprotic solvent, washed with drinking water and a weak base, and dried with a desiccant to remove water to obtain an intermediate solution. Then, catalytic Lewis acid and triethyl phosphite are added, and the reaction solution is heated to 30-50°C and stirred for 6-12 hours. After the reaction is completed, the mixture is cooled slightly, washed with drinking water, and the liquid is separated into different layers. The organic layer is concentrated to dryness under reduced pressure to obtain the compound of formula VI, which is used directly in the next reaction step without purification.

[0086] The weight ratio of compound V, halogen acid and sulfuric acid is preferably compound V: halogen acid: sulfuric acid=1.0: 1.5-2.0: 0.5-0.8 The reaction time is preferably 8-12 hours.

[0087] The weak base is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate or potassium bicarbonate. The drying agent is anhydrous magnesium sulfate or anhydrous sodium sulfate.

[0088] In the step (b-2), intermediate VI is reacted with 5-chlorosalicylaldehyde VII via the Horner-Wadsworth-Emmons reaction to obtain intermediate VIII.

[0089] The molar ratio of intermediate VI to 5-chlorosalicylaldehyde in this step was intermediate VI:5-chlorosalicylaldehyde=1.0:1.2.

[0090] The base used may be selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, sodium bicarbonate, potassium bicarbonate, potassium tert-butoxide, sodium tert-butoxide or a mixture of two or more thereof.

[0091] The reaction solvent is an aprotic solvent and may be selected from benzene, toluene, xylene, chlorobenzene, tetrahydrofuran, methyltetrahydrofuran, isopropyl ether, methyl tert-butyl ether, or a mixture of two or more thereof.

[0092] The reaction temperature is -5 to 25°C, preferably -5 to 10°C.

[0093] In the above step (b-3), intermediate VIII is acetylated with acetic anhydride under basic conditions to obtain intermediate IX.

[0094] The molar ratio of intermediate VIII to acetic anhydride in this step is intermediate VIII:acetic anhydride=1.0:1.8, preferably 1.2:1.5.

[0095] The base used may be selected from organic bases such as diethylamine, triethylamine, isopropylethylamine, pyridine or p-dimethylaminopyridine, or inorganic bases such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, sodium hydride or potassium hydride.

[0096] The reaction solvent may be selected from benzene, toluene, xylene, chlorobenzene, tetrahydrofuran, methyltetrahydrofuran, isopropyl ether, methyl tert-butyl ether, or a mixture of two or more thereof.

[0097] The reaction temperature is 5 to 55°C.

[0098] For post-treatment, water, methanol, ethanol or isopropanol can be added to precipitate compound IX.

[0099] In the above step (b-4), intermediate IX is reacted with N-(alkoxymethyl)-N-methyl-(trimethylsilyl)methylamine in an aprotic solvent under the catalysis of trifluoroacetic acid at ambient temperature to carry out a Huisgen cycloaddition reaction, and then deprotected under basic conditions to obtain intermediate II.

[0100] In the compound of formula X, R is C 1-6 R may be alkyl, preferably -CH 3 and -Bu-n.

[0101] The molar ratio of intermediate IX to the compound of formula X in this step is intermediate IX:compound X=1.0:1.5, preferably 1.1:1.3.

[0102] The reaction solvent in this step may be selected from benzene, toluene, xylene, chlorobenzene, tetrahydrofuran, methyltetrahydrofuran, isopropyl ether, methyl tert-butyl ether or a mixture of two or more of the aforementioned solvents.

[0103] The solvent used in the deacetylation is C 1-4 The alcohol solvent is selected from methanol, ethanol, propanol, isopropanol or butanol. The base used is an aqueous alkali metal solution, which may be selected from aqueous lithium hydroxide, sodium hydroxide or potassium hydroxide.

[0104] In a fifth aspect, the present invention provides a compound of formula II

[0105] [ka] Another method for preparing a compound of the formula:

[0106] In the above step (c-1), sulfuric acid and hydrohalic acid are allowed to act on compound (V) to replace the hydroxyl groups in the structure with halogen atoms, and the compound is then reacted with triphenylphosphine in an aprotic organic solvent to obtain intermediate XI.

[0107] The hydrohalic acids used in this process include various concentrations of hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid.

[0108] The aprotic organic solvent used may be selected from dichloromethane, chloroform, tetrahydrofuran, methyltetrahydrofuran, benzene, toluene, xylene, chlorobenzene or a mixture of two or more thereof.

[0109] Specifically, compound V (2-halo-5-nitro-benzyl alcohol), hydrohalic acid and sulfuric acid are mixed in a weight ratio of 1.0:1.0-3.0:0.2-1.0 equivalents, and then heated to 20-85°C. The reaction mixture is maintained at that temperature with stirring for 5-14 hours, then extracted with an aprotic solvent, washed with drinking water and a weak base, and dried with a desiccant to remove water to obtain an intermediate solution. Then, triethyl phosphite is added, and the reaction solution is heated to 30-70°C and stirred for 6-12 hours. After the reaction is completed, the mixture is cooled to room temperature and filtered to obtain the compound of formula XI.

[0110] The weight ratio of compound V, halogen acid, and sulfuric acid is preferably compound V: halogen acid: sulfuric acid=1.0: 1.2-1.5: 0.2-0.5 The reaction time is preferably 8-12 hours.

[0111] The weak base is selected from one or more of sodium carbonate, potassium carbonate, cesium carbonate, sodium bicarbonate or potassium bicarbonate. The drying agent is anhydrous magnesium sulfate or anhydrous sodium sulfate.

[0112] In the above step (c-2), intermediate XI is reacted with 5-chlorosalicylaldehyde VII under basic conditions via a Wittig reaction to obtain intermediate VIII.

[0113] The base used in this step may be selected from inorganic bases such as lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium tert-butoxide or potassium tert-butoxide, or organic bases such as triethylamine, pyridine, p-dimethylaminopyridine or diisopropylethylamine.

[0114] In this step, the molar ratio of intermediate XI to 5-chlorosalicylaldehyde is 1:1.05-1.5, preferably 1:1.05-1.3.

[0115] The reaction temperature is 20 to 80°C, preferably 40 to 70°C.

[0116] The reaction solvent is an aprotic organic solvent and may be selected from dichloromethane, chloroform, tetrahydrofuran, methyltetrahydrofuran, benzene, toluene, xylene, chlorobenzene, or a mixture of two or more thereof.

[0117] In the above step (b-3), intermediate VIII is acetylated with acetic anhydride under basic conditions to obtain intermediate IX.

[0118] The molar ratio of intermediate VIII to acetic anhydride in this step is intermediate VIII:acetic anhydride=1.0:1.8, preferably 1.2:1.5.

[0119] The base used may be selected from organic bases such as diethylamine, triethylamine, isopropylethylamine, pyridine or p-dimethylaminopyridine, or inorganic bases such as sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, cesium carbonate, sodium hydride or potassium hydride.

[0120] The solvent used in the reaction is selected from one or more of benzene, toluene, xylene, chlorobenzene, tetrahydrofuran, methyltetrahydrofuran, isopropyl ether and methyl tert-butyl ether.

[0121] The reaction temperature is 5 to 55°C.

[0122] For post-treatment, water, methanol, ethanol or isopropanol can be added to precipitate compound IX.

[0123] In the above step (b-4), intermediate IX is reacted with N-(alkoxymethyl)-N-methyl-(trimethylsilyl)methylamine in an aprotic solvent under the catalysis of trifluoroacetic acid at ambient temperature to carry out a Huisgen cycloaddition reaction, and then deprotected under basic conditions to obtain intermediate II.

[0124] In the compound of formula X, R is C 1-6 R may be alkyl, preferably -CH 3 and -Bu-n.

[0125] The molar ratio of intermediate IX to the compound of formula X in this step is intermediate IX:compound X=1.0:1.5, preferably 1.1:1.3.

[0126] The reaction solvent in this step may be selected from benzene, toluene, xylene, chlorobenzene, tetrahydrofuran, methyltetrahydrofuran, isopropyl ether, methyl tert-butyl ether or a mixture of two or more of the aforementioned solvents.

[0127] The solvent used in the deacetylation is C 1-4 The alcohol solvent is selected from methanol, ethanol, propanol, isopropanol or butanol. The base used is an aqueous alkali metal solution, which may be selected from aqueous lithium hydroxide, sodium hydroxide or potassium hydroxide.

[0128] The key point of the present invention involves using Lewis acid catalysis to react 2-halo-5-nitrobenzyl halide with triethyl phosphite under mild reaction conditions to obtain intermediate IV, thereby avoiding the use of high temperature and long reaction time with 2-bromo-benzyl bromide to prepare phosphonates as described in the prior art (US2008009619). Due to the strong electrophilic effect of the nitro group at the para-position of the halogen atom on the tetrahydropyrrole-benzene ring of intermediate II, an intramolecular nucleophilic substitution reaction occurs between the halogen atom and the phenolic hydroxyl group on the other benzene ring under basic and mild conditions to generate a dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole ring, thus overcoming the disadvantage that the structure of the dibenzo[2,3:6,7]oxepino[4,5-c]pyrrole ring of asenapine in the prior art (US2008009619) requires a long and high temperature intramolecular Ullmann reaction. Furthermore, the purification method of asenapine is improved, and a new crystalline form of asenapine free base is obtained. The crystallization method and the obtained crystals can simplify post-treatment operations, improve purification efficiency, and reduce costs, and are therefore very advantageous for large-scale industrial production.

[0129] Compared with the prior art, the method for preparing asenapine according to the present invention does not use the dangerous, flammable and explosive reducing agent LiAlH used in the prior art (US4145434, Org. Process Res. Dev., 2008, 12(2), 196-201, CN102229613, CN104974168). 4 The present invention avoids the use of butyllithium and methyl iodide, and avoids the process of isomer separation and purification, thereby simplifying the procedure. Furthermore, the method of the present invention does not require high temperature and long reaction operation (US2008009619), avoids the use of dangerous and highly toxic reagents butyllithium and methyl iodide (CN102229613), and does not use methyl iodide, boron tribromide and hydrazine hydrate (CN104974168). The present invention has advantages including mild reaction conditions, simple operation, less environmental pollution, low cost, etc., and is therefore more suitable for industrial production. [Brief description of the drawings]

[0130] [Figure 1] FIG. 1 is a powder X-ray diffraction (PXRD) pattern of asenapine crystals of the present invention. [Diagram 2] 1 is an IR pattern of the asenapine crystals of the present invention. [Diagram 3] 1 is a DSC pattern of asenapine crystals of the present invention. EXAMPLES

[0131] The method of the present invention is further illustrated by the following examples. It should be understood that the following examples are provided to aid in a better understanding of the present invention and are not intended to limit the scope of the present invention in any way.

[0132] [Example 1]

[0133] [ka]

[0134] Step (b-1): Synthesis of Compound VI In a 200 ml reaction flask, 35.2 g of compound V and 63.3 g of 48% aqueous hydrobromic acid were added, followed by dropwise addition of 18.4 g of sulfuric acid at room temperature. The mixture was warmed to 50° C., maintained at this temperature for 10 hours, cooled to room temperature, and then 100 ml of dichloromethane was added. The organic layer was washed with 50 ml of water and 50 ml of aqueous sodium carbonate, dried by adding 10 g of sodium sulfate, and filtered. To the organic layer, 63.1 g of triethyl phosphite and 8.6 g of anhydrous zinc bromide were added in one portion. The reaction mixture was heated to 40° C., stirred for 10 hours, cooled slightly, and then 100 ml of water was added to wash it. The aqueous layer was discarded, the organic layer was collected, and the solvent was evaporated under reduced pressure to give compound VI (54.8 g, 95.0%).

[0135] Step (b-2): Synthesis of Compound VIII Under nitrogen protection, 54.0 g of compound VI was dissolved in 500 ml of tetrahydrofuran, and 30.1 g of 5-chlorosalicylaldehyde was added thereto. The mixture was cooled to 0° C., and 39.2 g of potassium tert-butoxide was added in small portions while maintaining the temperature at 0° C. After the reaction was completed, 300 ml of water and 300 ml of toluene were added. The organic layer was washed with sodium carbonate solution and 200 ml of saturated sodium chloride solution. The organic layer was evaporated to dryness under reduced pressure at 50° C. to give compound VIII (52.9 g, 97.2%).

[0136] Step (b-3): Synthesis of compound IX Under nitrogen protection, 52.0 g of compound VIII, 17.1 g of pyridine, and 200 ml of toluene were added, and 21.7 g of acetic anhydride was added dropwise at room temperature. The reaction was maintained overnight. The mixture was heated to 50° C., and 41 ml of water and 13 ml of ethanol were added thereto, and the temperature was maintained for 30 minutes. The mixture was cooled to room temperature and filtered to obtain product IX (58.2 g, 98.5%). 1 H NMR (400 MHz, CDCl 3 ) δ (ppm): 8.48 (d, 1H), 8.07-8.10 (dd, 1H), 8.67-8.68 (d, 1H), 7.57-7.60 (d, 1H), 7.44-7.48 (d, 1H), 7.31-7.34 (dd, 1H), 7.14-7.18 (d, 1H), 7.08-7.10 (d, 1H), 2.41 (s, 3H).

[0137] Step (b-4): Synthesis of Compound II 58.0 g of compound IX was dissolved in 500 ml of toluene in a reaction flask, to which 0.5 g of trifluoroacetic acid was added. 32.7 g of N-(methoxymethyl)-N-methyl-(trimethylsilyl)methylamine was added dropwise within 1 hour, and the mixture was maintained at ambient temperature for 3 hours. The organic layer was concentrated under vacuum to obtain an oil. The oil was dissolved in 400 ml of methanol, and an aqueous potassium hydroxide solution (10.5 g of potassium hydroxide dissolved in 90 ml of water) was added. After 1 hour, the pH was adjusted to 8-9 with 3N hydrochloric acid. The mixture was stirred for 30 minutes and filtered. The resulting product was dried under vacuum for 10 hours to obtain compound II (56.0 g, 92.6%). 1 H NMR (400 MHz, CDCl 3 ) δ (ppm): 12.39 (s, -OH), 8.26 (s, 1H), 8.04-8.06 (d, 1H), 7.52-7.54 (d, 1H), 7.05-7.06 (d, 1H), 6.81-6.83 (d, 1H), 6.76 (s, 1H), 4.13 (s, 1H), 3.67-3.70 (t, 1H), 3.31 (s, 1H), 3.24-3.26(d, 1H), 2.95-2.98(t, 1H), 2.57(s, 3H), 2.37-2.41(t, 1H). 13 C NMR (101 MHz, CDCl 3 ) δ (ppm): 154.75, 147.05, 142.12, 141.12, 131.30, 131.13, 129.44, 128.45, 123.34, 123.02, 122.79, 119.43, 63.23, 61.66, 51.42, 48.24, 39.95.

[0138] Step (a-1): Synthesis of Compound III Under nitrogen protection, 50.0 g of compound II and 250 ml of tetrahydrofuran were added to a reaction flask. The mixture was stirred, and then 22.6 g of potassium carbonate was added. The mixture was warmed to 50-60°C and the temperature was maintained for 3 hours. The mixture was cooled to ambient temperature, and then 750 ml of water was added dropwise. The mixture was stirred for 30 minutes and filtered. The product was dried under vacuum to give compound III (43.1 g, 95.6%). 1 H NMR (400 MHz, CDCl 3 ) δ (ppm): 8.07-8.10 (dd, 1H), 7.98-7.99 (d, 1H), 7.26-7.29 (d, 1H), 7.18-7.21 (m, 1H), 7.13-7.15 (d, 2H), 3.66-3.73 (m, 1H), 3.52-3.60 (m, 1H), 3.30-3.35 (m, 1H), 3.13-3.23 (m, 3H), 2.57 (s, 3H). 13 C NMR (101 MHz, CDCl 3 ) δ (ppm): 159.71, 153.14, 143.59, 133.89, 132.45, 130.12, 127.88, 126.27, 123.58, 122.39, 121.91, 59.66, 58.35, 45.74, 44.39, 42.97. MS (ESI): m / z = 330.08, [M + H] + = 331.08.

[0139] Step (a-2): Synthesis of Compound IV Compound III (42.0 g) was dissolved in 500 ml of methanol, to which 4.0 g of the activated nickel wet product was added. The air was evacuated, the mixture was heated to 60°C, and hydrogen was introduced to react for 6 to 8 hours. The mixture was filtered to remove nickel, and the reaction solution was concentrated under vacuum to obtain an oil. The oil was dissolved in 250 ml of methanol, and 250 ml of water was added with stirring, and the mixture was stirred for 30 minutes and filtered. The product was dried under vacuum to obtain compound IV (36.4 g, 95.4%).

[0140] Step (a-3): Synthesis of Compound I (asenapine) 36.0 g of compound IV was dissolved in 117 g of hypophosphorous acid, cooled to 10-20°C, and 31.2 g of 30% aqueous solution of sodium nitrite was added dropwise thereto, and the addition was completed after 3-4 hours. After the completion of the addition, the temperature was kept at 10-20°C, and the mixture was stirred for 6-8 hours. 78.0 g of ammonia solution was added dropwise while maintaining the temperature below 30°C. The pH of the aqueous layer was adjusted to 8-9, and 156 ml of n-heptane was added thereto. The organic layer was washed with 78 ml of water. The organic layer was then evaporated to dryness under reduced pressure at 50°C to obtain a crude product.

[0141] To the crude product, 110 ml of n-heptane and 8.0 ml of toluene were added. After heating to 40-50°C and stirring to dissolve the crude product, the solution was cooled at a rate of 5-10°C / h to crystallize. The solution was cooled to 20-25°C and stirred for 1.0-1.5 hours to precipitate crystals. After a large amount of solid precipitated, the solution was cooled to -5-0°C and stirred for 1.0 hour while maintaining the temperature. The solution was filtered to recover the crystalline asenapine and dried under vacuum at 40-45°C to obtain the compound in crystalline form (30.6 g, 89.5%, HPLC purity >99%). 1 H NMR (400 MHz, CDCl 3 ) δ (ppm): 7.14-7.20 (m, 2H), 7.11 (s, 2H), 7.05-7.09 (m, 3H), 3.58-3.68 (m, 2H), 3.18-3.25 (m, 2H), 3.08-3.16 (m, 2H), 2.55 (s, 3H). 13 C NMR (101 MHz, CDCl 3 ) δ (ppm): 155.22, 151.14, 134.01, 131.88, 128.91, 127.64, 127.33, 126.79, 126.71, 124.15, 122.35, 120.90, 59.12, 59.00, 44.83, 44.72, 43.25. MS (ESI): m / z = 285.09, [M + H] += 286.10.

[0142] [Example 2]

[0143] [ka]

[0144] Compound IV (73.0 g) was dissolved in hypophosphorous acid (220 g), cooled to 0-15°C, and 30% aqueous solution of sodium nitrite (64.0 g) was added dropwise thereto, and the addition was completed after 2-3 hours. After the addition was completed, the temperature was kept at 10-20°C, and the mixture was stirred for 5-9 hours. Ammonia solution (160 g) was added dropwise while maintaining the temperature below 30°C. The pH of the aqueous layer was adjusted to 8-9, and 300 ml of n-hexane was added thereto. The organic layer was washed with water (160 ml). The organic layer was then evaporated to dryness under reduced pressure at 45-50°C to obtain a crude product.

[0145] To the crude product, 230 ml of n-heptane and 17 ml of toluene were added. After heating to 40-50°C and stirring to dissolve the crude product, the solution was cooled at a rate of 5-10°C / h to crystallize. The solution was cooled to 20-25°C and stirred for 1.0-1.5 hours to precipitate crystals. After a large amount of solid precipitated, the solution was cooled to -5-0°C and stirred for 1.0 hour while maintaining the temperature. The solution was filtered to recover the crystalline asenapine and dried under vacuum at 40-45°C to obtain the compound in crystalline form (63.3 g, 91.2%, HPLC purity >99%).

[0146] [Example 3]

[0147] [ka]

[0148] Step (c-1): Synthesis of compound XI In a 250 ml reaction flask, 50.0 g of compound V and 75.0 g of 48% aqueous hydrobromic acid were added, and 14.0 g of sulfuric acid was added thereto at room temperature. The reaction mixture was heated to 60° C. and the temperature was maintained for 13 hours. The reaction mixture was cooled to room temperature, and 100 ml of toluene was added thereto. The organic layer was washed with 35.0 g of water and 28.0 g of 2.5% aqueous sodium carbonate solution. The solution was allowed to stand, and the layers were separated. 65.2 g of triphenylphosphine was added to the organic layer. The resulting mixture was stirred at 60° C. for 10 hours, then cooled to ambient temperature and filtered to obtain compound XI (118.8 g, 95.2%).

[0149] Step (c-2): Synthesis of Compound VIII Under nitrogen, 102.4g of compound XI was dissolved in 1000ml of tetrahydrofuran, and 37.4g of 5-chlorosalicylaldehyde was added. 15.8g of pyridine was added dropwise. After the reaction was completed, 600ml of water and 600ml of hexane were added. The organic layer was washed with 400ml of sodium carbonate solution, followed by saturated sodium chloride solution. The organic layer was evaporated to dryness under reduced pressure at 50°C, and compound VIII (62.8g, 92.6%) was isolated by column chromatography.

[0150] Step (b-3): Synthesis of compound IX Under nitrogen protection, 60.0 g of compound VIII, 21.5 g of triethylamine, and 230 ml of tetrahydrofuran were added, and 33.4 g of acetic anhydride was added dropwise thereto at 15-30°C. The reaction was maintained overnight. The reaction mixture was heated to 45°C, and 46 ml of water and 15 ml of ethanol were added thereto. The temperature was maintained for 30 minutes. The mixture was cooled to room temperature and filtered to obtain product IX (66.8 g, 98.0%).

[0151] Step (b-4): Synthesis of Compound II 65.0 g of compound IX was added and dissolved in 540 ml of tetrahydrofuran in a reaction flask, to which 1.0 g of trifluoroacetic acid was added. 37.0 g of N-(methoxymethyl)-N-methyl-(trimethylsilyl)methylamine was added dropwise within 1 hour. The reaction mixture was kept at ambient temperature for 3 hours. The organic layer was concentrated under vacuum to obtain an oil. The oil was dissolved in 435 ml of ethanol. An aqueous solution of potassium hydroxide (13.7 g of potassium hydroxide dissolved in 117 ml of water) was added. After 1 hour, the pH was adjusted to 8-9 with 3N hydrochloric acid. The mixture was stirred for 30 minutes and filtered. The product was dried under vacuum for 11 hours to obtain compound II (62.4 g, 92.0%).

[0152] [Example 4] Method for preparing crystals of asenapine having formula I To 60.0 g of asenapine crude product, 180 ml of n-heptane and 15 ml of toluene were added. After heating to 35-45°C and stirring to dissolve the crude product, the solution was cooled at a rate of 5-10°C / hr to crystallize. The solution was cooled to 15-25°C and stirred for 1.0 hour while maintaining the temperature. The solution was then cooled to -20--10°C and stirred for 1.0 hour while maintaining the temperature. The solution was filtered and the crystalline asenapine was collected and dried under vacuum at 35-45°C to obtain crystalline asenapine of formula I (55.2 g, 92.0%, HPLC purity >99%).

[0153] [Example 5] Method II for preparing crystals of asenapine having formula I 300 g of ethanol was added to 95.0 g of crude asenapine. The mixture was warmed to 40-50°C to dissolve the crude product. Then, the temperature was controlled at 30-40°C. 45 g of purified water was added dropwise. The solution was cooled to 20-25°C and the temperature was maintained for 1.0-1.5 hours to precipitate crystals. Then, the solution was slowly cooled to 0-5°C and stirred for 1 hour while maintaining the temperature. The solution was filtered. The obtained solid was rinsed with an appropriate amount of aqueous ethanol solution, filtered and dried to obtain a wet product. The product was dried under vacuum at 50-60°C to obtain a crystalline form of asenapine of formula I (91.4 g, 96.2%, HPLC purity >99%).

[0154] [Example 6] Method III for preparing crystals of asenapine having formula I At room temperature, 400 g of hexane was added to 3.0% aqueous sodium hydroxide solution, and then 84.0 g of asenapine maleate was added in small portions. The mixture was stirred to dissolve, and then the layers were separated. The aqueous layer was extracted with 150 g of hexane. The organic layers were combined and washed twice with 150 g of water. The organic layers were concentrated to dryness under reduced pressure. 200 g of hexane and 20 g of ethyl acetate were added to the reaction system. The mixture was heated to 45-55°C and stirred to dissolve. The solution was cooled to 15-25°C, and the temperature was maintained for 1.5 hours to precipitate crystals. The solution was then cooled to -15-10°C and filtered. The product was collected and dried in vacuum at 35-45°C to obtain asenapine of formula I in crystalline form (69.3 g, 93.1%, HPLC purity >99%). The following is one embodiment of the present invention. (1) Formula I [ka] A method for preparing asenapine of formula (I), comprising the steps of: (a-1) A step of subjecting intermediate II to an intramolecular nucleophilic substitution reaction under basic conditions to obtain a cyclic ether intermediate III [ka] wherein X is F, Cl, Br or I, and the base is an alkali metal hydroxide, an alkali metal carbonate, an alkali metal bicarbonate, a metal hydride, an organometallic compound or a strong non-nucleophilic organic base; (a-2) reducing the nitro group of intermediate III to obtain intermediate IV; [ka] (a-3) subjecting intermediate IV to a diazotization deamination reaction and then purifying it by recrystallization to obtain the pure product asenapine of formula I. [ka] The method according to claim 1, further comprising: (2) In the step (a-1), the base used is LiOH, NaOH, KOH, RbOH, CsOH, FrOH, Li 2 CO 3 , Na 2 CO 3 、K 2 CO 3 , Rb2 CO 3 , Cs 2 CO 3 , LiHCO 3 , NaHCO 3 , K.H.C.O. 3 , NaH, KH, CaH 2 butyllithium, methylmagnesium chloride, tert-butylmagnesium chloride, ethylmagnesium bromide, butylmagnesium bromide, LDA, LiHMDS or NaHMDS. (3) A method for preparing asenapine of formula I according to any one of (1) and (2), characterized in that in the step (a-1), the solvent used in the reaction is an aprotic solvent, for example, selected from toluene, xylene, tetrahydrofuran, methyltetrahydrofuran, diethyl ether, isopropyl ether, methyl tert-butyl ether, dioxane, acetonitrile, sulfolane, N-methylpyrrolidone, DMF, DMSO, glycol dimethyl ether, diglycol dimethyl ether or a mixture of two or more thereof. (4) A method for preparing asenapine of formula I according to any one of (1) to (3), characterized in that in the step (a-3), the reducing agent used in the diazotization deamination reaction is methanol, ethanol, isopropanol, hypophosphorous acid, sodium borohydride, potassium borohydride or a nitrite. (5) In the step (a-3), the solvent used in the purification by recrystallization is C 5-9 A method for preparing asenapine of formula I according to any of (1) to (4), characterized in that the solvent is selected from an alkane (e.g., n-pentane, hexane, n-hexane or n-heptane or a mixture of two or more thereof), an aromatic hydrocarbon solvent (e.g., benzene, toluene, xylene, chlorobenzene or a mixture of two or more thereof), an ester solvent (e.g., ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, tert-butyl acetate or a mixture of two or more thereof), a ketone solvent (e.g., acetone, butanone or a mixture thereof), an ether solvent (e.g., diethyl ether, isopropyl ether, methyl tert-butyl ether, tetrahydrofuran, methyltetrahydrofuran or a mixture of two or more thereof), an alcohol solvent (e.g., methanol, ethanol, propanol, isopropanol or a mixture of two or more thereof), water, or a mixture of two or more of the above solvents, preferably n-heptane or a mixture thereof with another solvent. (6) A process for preparing asenapine of formula I, comprising the steps of: The intermediate IV is subjected to a diazotization deamination reaction and then purified by recrystallization to obtain the pure product asenapine of formula I, as follows:

change

change

change

change

change

Claims

1. Formula I 【Chemistry 1】 A method for preparing asenapine of formula (I), comprising the steps of: (a-1) A step of subjecting intermediate II to an intramolecular nucleophilic substitution reaction under basic conditions to obtain a cyclic ether intermediate III 【Chemistry 2】 wherein X is F, Cl, Br or I, and the base is an alkali metal hydroxide, an alkali metal carbonate, an alkali metal bicarbonate, a metal hydride, an organometallic compound or a strong non-nucleophilic organic base; (a-2) reducing the nitro group of intermediate III to obtain intermediate IV; 【Chemistry 3】 (a-3) subjecting intermediate IV to a diazotization deamination reaction and then purifying it by recrystallization to obtain the pure product asenapine of formula I. 【Chemistry 4】 The method according to claim 1, further comprising:

2. In the step (a-1), the base used is LiOH, NaOH, KOH, RbOH, CsOH, FrOH, Li 2 CO 3 , Na 2 CO 3 , K 2 CO 3 , Rb 2 CO 3 , Cs 2 CO 3 , LiHCO 3 , NaHCO 3 , K.H.C.O. 3 , NaH, KH, CaH 2 butyllithium, methylmagnesium chloride, tert-butylmagnesium chloride, ethylmagnesium bromide, butylmagnesium bromide, LDA, LiHMDS or NaHMDS.

3. 3. A process for preparing asenapine of formula I according to any one of claims 1 and 2, characterized in that in step (a-1), the solvent used in the reaction is an aprotic solvent selected from toluene, xylene, tetrahydrofuran, methyltetrahydrofuran, diethyl ether, isopropyl ether, methyl tert-butyl ether, dioxane, acetonitrile, sulfolane, N-methylpyrrolidone, DMF, DMSO, glycol dimethyl ether, diglycol dimethyl ether or a mixture of two or more thereof.

4. A process for preparing asenapine of formula I according to any one of claims 1 to 3, characterized in that in step (a-3), the reducing agent used in the diazotization deamination reaction is methanol, ethanol, isopropanol, hypophosphorous acid, sodium borohydride, potassium borohydride or a nitrite.

5. In the step (a-3), the solvent used in the purification by recrystallization is C 5-9 A process for preparing asenapine of formula I according to any one of claims 1 to 4, characterized in that the solvent is selected from alkanes, aromatic hydrocarbon solvents, ester solvents, ketone solvents, ether solvents, alcohol solvents, water or a mixture of two or more of the above mentioned solvents.

6. A method for preparing asenapine of formula I as described in claim 5, characterized in that in step (a-3), the solvent used in purification by recrystallization is selected from n-pentane, hexane, n-hexane, n-heptane, benzene, toluene, xylene, chlorobenzene, ethyl formate, methyl acetate, ethyl acetate, propyl acetate, isopropyl acetate, butyl acetate, tert-butyl acetate, acetone, butanone, diethyl ether, isopropyl ether, methyl tert-butyl ether, tetrahydrofuran, methyltetrahydrofuran, methanol, ethanol, propanol, isopropanol, water, or a mixture of two or more of the above solvents.

7. A method for preparing asenapine of formula I as described in claim 6, characterized in that in step (a-3), the solvent used in purification by recrystallization is n-heptane or a mixture thereof with other solvents.

8. A process for preparing asenapine of formula I, comprising: The intermediate IV is subjected to a diazotization deamination reaction and then purified by recrystallization to obtain the pure product asenapine of formula I, as follows: 【Chemistry 5】 The method includes:

9. 9. The method according to claim 8, wherein the reducing agent used in the diazotization deamination reaction in the step is methanol, ethanol, isopropanol, hypophosphorous acid, sodium borohydride, potassium borohydride or a nitrite.

10. Formula II 【Chemistry 6】 wherein X is F, Cl, Br or I.

11. A method for preparing a compound of formula II, comprising the steps of: 【Chemistry 7】 wherein X is F, Cl, Br or I; Step (b-1): A step of reacting compound (V) with sulfuric acid and hydrohalic acid to replace the hydroxyl group in the structure with a halogen atom, and then reacting the compound with triethyl phosphite in an aprotic organic solvent under the catalytic action of a Lewis acid to obtain intermediate VI; Step (b-2): reacting intermediate VI with 5-chlorosalicylaldehyde VII via Horner-Wadsworth-Emmons reaction to obtain intermediate VIII; Step (b-3): acetylating the intermediate VIII with acetic anhydride under basic conditions to obtain the intermediate IX; and Step (b-4): reacting intermediate IX with N-(alkoxymethyl)-N-methyl-(trimethylsilyl)methylamine (X) under the catalytic action of trifluoroacetic acid to carry out a Huisgen cycloaddition reaction to obtain intermediate II, wherein R is C 1-6 is alkyl, The method includes:

12. In step (b-1), the hydrohalic acid used includes hydrofluoric acid, hydrochloric acid, hydrobromic acid, or hydroiodic acid, and the Lewis acid is FeCl 2 , FeCl 3 , FeBr 3 , ZnCl 2 , ZnBr 2 or InBr 2 and / or the aprotic organic solvent is selected from dichloromethane, chloroform, tetrahydrofuran, methyltetrahydrofuran, benzene, toluene, xylene, chlorobenzene, or a mixture of two or more thereof.

13. 13. The process according to claim 11, characterized in that in step (b-2) the base used is selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, lithium carbonate, sodium carbonate, potassium carbonate, sodium hydrogen carbonate, potassium hydrogen carbonate, potassium tert-butoxide or sodium tert-butoxide.

14. In the compound of formula X in step (b-4), R is C 1-4 The method according to any one of claims 11 to 13, characterized in that it is alkyl.

15. The method according to claim 14, wherein in the compound of formula X in step (b-4), R is methyl or n-butyl.

16. A method for preparing a compound of formula II, comprising the steps of: 【Chemistry 8】 (wherein X is F, Cl, Br or I). Step (c-1): A step of reacting compound (V) with sulfuric acid and hydrohalic acid to replace the hydroxyl group in the structure with a halogen atom, and then reacting the compound with triphenylphosphine in an aprotic organic solvent to obtain intermediate XI; Step (c-2): reacting intermediate XI with 5-chlorosalicylaldehyde VII under basic conditions via a Wittig reaction to obtain intermediate VIII; Step (b-3): acetylating the intermediate VIII with acetic anhydride under basic conditions to obtain the intermediate IX; and Step (b-4): reacting intermediate IX with N-(alkoxymethyl)-N-methyl-(trimethylsilyl)methylamine (X) under the catalytic action of trifluoroacetic acid to carry out a Huisgen cycloaddition reaction to obtain intermediate II, wherein R is C 1-6 is alkyl, The method includes:

17. The method according to claim 16, wherein in the compound of formula X in step (b-4), R is methyl or n-butyl.

18. 18. The process according to any one of claims 16 and 17, characterized in that in step (c-1) the hydrohalic acid used is selected from hydrofluoric acid, hydrochloric acid, hydrobromic acid or hydroiodic acid, and / or the aprotic organic solvent used is selected from dichloromethane, chloroform, tetrahydrofuran, methyltetrahydrofuran, benzene, toluene, xylene, chlorobenzene or a mixture of two or more thereof.

19. The process according to any one of claims 16 to 18, characterized in that in step (c-2), the base used is selected from lithium hydroxide, sodium hydroxide, potassium hydroxide, sodium carbonate, potassium carbonate, sodium tert-butoxide, potassium tert-butoxide, triethylamine, pyridine, p-dimethylaminopyridine or diisopropylethylamine.

Citation Information

Patent Citations

  • New process for synthesis of asenapine

    CN102229613A

  • Preparation method of asenapine and intermediate used for preparing asenapine

    CN104974168A

  • Purification method of asenapine

    CN107759609A

  • A method for preparing asenapine, and an intermediate product used in the said method.

    JP2010503611A

  • Process for preparing 8-hydroxyclomipramine or its pharmaceutically acceptable salt

    KR1020150107357A